The FDA first approved Stivarga in September 2012 to treat colorectal cancer patients who don’t respond to initial treatments. Now, the drug can also be used as a second-line treatment for hepatocellular carcinoma, the most common type of liver cancer.
Stivarga’s expanded approval marks the first new treatment for liver cancer in nearly a decade, according to the FDA.
More articles on supply chain:
Corporate Whistleblower Center encourages pharma employees to report unsanitary drug plant conditions
7 must-reads for supply chain leaders this week
Dem. Senators pen letter to Dr. Scott Gottlieb on FDA hiring freeze
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
